Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on August 4, 2017, covering events occurring on August 3, 2017. The filing details the Company's entry into a material definitive agreement for a public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
The filing describes a firm commitment underwritten public offering with the following terms:
- Offering Size: 1,648,484 shares of Common Stock and warrants to purchase an equal number of shares.
- Offering Price: $4.125 per share.
- Gross Proceeds: Approximately $6,800,000.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 247,272 additional shares and warrants.
- Underwriting Commission: 7.0% of gross proceeds.
- Representative's Warrant: 65,940 shares with an exercise price of $4.5375 (110% of public offering price), exercisable starting August 3, 2018.
- Warrant Terms: Public warrants are exercisable immediately at $4.125 and expire five years from issuance.
The filing text does not provide specific values for the Company's historical revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Outlook
The primary material change is the execution of the underwriting agreement with Aegis Capital Corp. (sole book-running manager) and Dawson James Securities, Inc. (co-manager). The registration statement (Form S-1, File No. 333-217956) became effective on August 2, 2017. The Company also entered into a Warrant Agent Agreement with VStock Transfer, LLC.
Management commentary and specific financial guidance are not included in this filing; however, the press release referenced in Item 8.01 indicates the Company is listing on the Nasdaq Capital Market.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds after deducting the 7.0% underwriting commission and other offering expenses.
- Confirm the listing status on the Nasdaq Capital Market as referenced in the press release.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Monitor the exercise of the 45-day over-allotment option by the underwriters.
- Check subsequent filings for the impact of the new equity issuance on the Company's cash position and capital structure.